The Globe and Mail reports in its Thursday, Oct. 19, edition that Eight Capital analyst Christian Sgro rates Healwell AI "buy" in new coverage. The Globe's David Leeder writes that Mr. Sgro is currently the lone analyst covering Healwell. Mr. Sgro set a share target of $1.50. Mr. Sgro calls Healwell AI "a unique growth opportunity at the intersection of healthcare and AI, offering scarcity value in the public markets." Mr. Sgro says in a note: "The company's mission is preventative care, leveraging technology to identify at-risk patients and drive better healthcare outcomes. With material financial and strategic alignment with Well Health (rated "buy," with a $10 share target), we believe Healwell is in the early innings of a data-driven land-grab strategy in healthtech." On Oct. 3, Well Health announced the acquisition of Healwell's clinical assets in Ontario and also became the lead investor in its $10-million convertible debenture offering, contributing $4-million. It became the largest shareholder in Healwell while forging a strategic alliance. Mr. Sgro calls Healwell's access to Well's practitioner network, which he estimates contains up to 25 per cent of all patients in Canada, a "competitive advantage."